Forbes James D

Director Forbes buys 5,000 XRAY shares at $12.48; doubles holdings to 10,000 shares amid -3.0% annual revenue decline, $-427.0M net loss.

Forbes James D purchased 5,000 shares at $12.48 on 2026-03-09, doubling his holdings from 5,000 to 10,000 shares and committing $62,400.00 to the position. This purchase occurred six days after a prior XRAY buy on 2026-03-03, indicating consecutive accumulation at depressed levels—the stock is currently trading at $12.80, down 24.0% from its 52-week high of $16.85. However, the company's fundamentals present significant headwinds: annual revenue declined 3.0% to $904.0M, and net income for the most recent full fiscal year was negative at $-427.0M, signaling operational distress that extends beyond temporary market weakness. The rapid succession of purchases by a director warrants attention, but without disclosure of his strategic rationale or knowledge of material developments, the timing of accumulation into a structurally unprofitable business cannot be isolated from broader market and company risk factors.

Director James D Forbes purchases 5,000 shares of XRAY at $13.47; stock now $13.30, down -29.3% from 52-week high of $18.81.

Director James D Forbes initiated a position in DENTSPLY SIRONA with a purchase of 5,000 shares at $13.47 on 2026-03-03, establishing his first recorded holding in the company. The transaction occurs in an environment where the stock has declined significantly from its 52-week high of $18.81 (now trading at $13.30, -29.3% from peak) and the company reported a net loss of $427.0M in its most recent quarter alongside negative annual revenue growth of -3.0%. The entry by a director warrants monitoring given the company's unprofitable state, though the scale of the initial purchase (5,000 shares for $67.3K) and recent positive momentum (30-day change: +6.7%, 90-day change: +17.3%) provide limited basis for drawing strong conclusions about directional conviction at this stage.